Researchers to Present Latest Clinical Evidence for Ekso GT Robotic Exoskeleton at ACRM 93rd Annual Conference

RICHMOND, Calif., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today announced that the company and its collaborators will exhibit the Ekso GT robotic exoskeleton at the American Congress of Rehabilitation in Medicine (ACRM) 93rd Annual Conference in Chicago, Illinois, taking place from October 30 to November 4, 2016. The conference, which is the world’s largest interdisciplinary rehabilitation research conference, has a theme this year of “Improving lives through interdisciplinary rehabilitation research.”

Ekso Bionics will host a Product Theater on November 2, 2016 from 6:00pm to 6:45pm at the ACRM EXPO Hall Product Theater, which will feature a presentation of the latest findings on exoskeletons and perspectives on the potential functional improvements that can be observed with use of Ekso GT. The presentation will also include a demonstration of the Ekso GT.

There are three presentations at ACRM dedicated to exoskeletons:

Wednesday, November 2, 2016

BLOCK 1: 11:00 am to 12:15 PM

  • Exoskeleton-Assisted Walking for Persons With Neurological Conditions: Part I - Review of Ongoing Clinical Trials (Gail Forrest, Ann Spungen, Kristen Hohl) #283 TEC, ST, CC

BLOCK 2: 2:15 to 3:30 PM

  • Exoskeleton-Assisted Walking for Persons With Neurological Conditions: Part II Exoskeleton Cases (Gail Forrest, Allan Kozlowski, Candy Tefertiller, Arun Jayaraman, Casey Kandilakis) #284 TEC, ND, CC

Thursday, November 3, 2016

BLOCK 5: 4:45 to 6:00 PM

  • Training Outcomes of Functional Electrical Stimulation, Testosterone, and Exoskeleton in Persons With Spinal Cord Injury (Ashraf Gorgey, Therese Johnston, Gail Forrest) #109 SCI, TEC

The following additional relevant educational session will be offered at ACRM:

Friday, November 4, 2016

BLOCK 6: 10:00 to 11:15 AM

  • Stroke: A Roadmap to Recovery (Cherie Hyder, Kathy Kniepmann, Jaclyn Schwartz, Shannon Scott) #232 ST, CP

BLOCK 7: 1:15 to 2:30 PM

  • Choosing Outcome Measures to Evaluate Functional Movement After Stroke: Are Resources Being Utilized Effectively? (Susan Lin, Jeanne Langan, Susan Fasoli, Pamela Bosch, Veronica Rowe) #156 ST, MES
  • Rehab Technology is Here to Stay: Making it Work in the Clinic (Deborah Backus, Kathryn Farris, Casey Kandilakis, Elizabeth Sasso) #126

Ekso Bionics will be exhibiting at booth numbers 300-302.

About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit:

About Ekso™ GT
Ekso GT is the first FDA cleared exoskeleton cleared for use with stroke and spinal cord injuries from L5 to C7. The Ekso GT with smart Variable Assist™ (marketed as SmartAssist outside the U.S.) software is the only exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of the patient’s body, challenging the patient as they progress through their continuum of care. The suit’s patented technology provides the ability to mobilize patients earlier, more frequently and with a greater number of high intensity steps. To date, this device has helped patients take more than 55 million steps in over 120 rehabilitation institutions around the world.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at The Company does not undertake to update these forward-looking statements.

Media Contact: Carrie Yamond/Rajni Dhanjani 212-867-1788 Investor Contact: Debbie Kaster 415-937-5403

Source:Ekso Bionics